Two Onc Docs

Dr. Spigel presents the ADRIATIC trial at ASCO 2024 focusing on Durvalumab in LS-SCLC. Topics include staging imaging, treatment approaches, trial results with improved outcomes, and future trials in small cell lung cancer space.

Dr Shikha Jain, founder of Women in Medicine & GI oncologist, shares tips for new doctors & attendings. Topics include teamwork in hospitals, importance of self-care, delivering bad news, continuous learning in medicine, essential tips for new doctors & attendings, and guidance for those in oncology.

Dr. Catherine Lai from UPenn discusses AML treatment options, including chemotherapy regimens based on core binding factors, variations in toxicity, and advancements like Gemtuzumab. She also explores recovery strategies, repeatable marrow biopsies, and different treatment approaches based on risk categories and patient fitness levels. The podcast ends with key takeaways on AML diagnosis criteria, induction regimens, specific treatment options for mutations, and the importance of seeking feedback.

Dr. Catherine Lai discusses AML classification, genetic mutations, and risk factors. Topics include treatment-related factors, hereditary myeloid malignancies, and managing leukostasis and tumor lysis syndrome in leukemia.

The podcast dives into the groundbreaking LAURA trial, showcasing how osimertinib post-chemoradiotherapy benefits patients with unresectable stage III EGFR-mutated NSCLC. It highlights advancements in staging and treatment, particularly the significance of the PACIFIC trial. Key findings reveal improved survival rates for patients on maintenance therapy. Discussions also cover the challenges of toxicity and indefinite treatment amidst unclear biomarkers, alongside the trial’s superiority over previous standards, reshaping treatment strategies for lung cancer.

Dr. Michael Atkins, a leading authority in metastatic melanoma and first author of the pioneering DREAMseq trial, delves into cutting-edge treatment options. He shares an inspiring case of an elderly patient and how immunotherapy can lead to rapid tumor regression. Discussion includes the impact of advanced therapies like BRAF-MEK inhibitors and the new Relatlimab-Nivolumab combination. Insights on treating brain metastases emphasize the need for teamwork in decision-making. Atkins also covers strategies for various melanoma subtypes and offers advice for budding oncologists.

Dr. Michael Atkins, a renowned expert and deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the latest in localized melanoma treatment. Breakthroughs in immunotherapy and targeted therapies are highlighted, showcasing improved survival rates. He dives into the critical staging process, emphasizing tumor thickness and lymph node involvement. The conversation also covers the effectiveness of neoadjuvant therapies like Pembrolizumab and the potential of oncolytic viruses in melanoma treatment, offering a glimpse into future clinical trials.

Dive into the intriguing world of genetic syndromes that elevate cancer risk, particularly focusing on renal cell carcinoma. Learn about the critical roles of syndromes like von Hippel-Lindau and the promising drug Belzutafan. Discover how genetic mutations influence cancer risks and unique clinical manifestations. The discussion highlights the importance of early detection and intervention in conditions like Hereditary Leiomyomatosis. Plus, gain insights into germline testing for solid tumors and its impact on effective risk management.

Dive into the intriguing world of genetic syndromes linked to higher cancer risks. Discover how Li-Fraumeni syndrome and P53 gene mutations shape patient care. Uncover the critical implications of Lynch Syndrome and its ties to secondary cancers. Learn about familial adenomatous polyposis (FAP) and the importance of proactive screenings. Explore the roles of BRCA1 and BRCA2 genes in DNA repair and their significance in cancer management. This enlightening discussion emphasizes tailored strategies for better health outcomes.

Dr. Tom Powles and Dr. Brian Rini, experts in urologic oncology and renal cell carcinoma, delve into groundbreaking updates for metastatic kidney cancer. They discuss the IMDC classification and its role in risk assessment, emphasizing patient selection for treatments. Treatment strategies, including the balance between aggressive therapies and patient well-being, are explored. The duo also addresses challenges in non-clear cell variants and highlights the potential of emerging therapies. Finally, they share valuable advice for early-career oncologists, stressing the importance of mentorship.